Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194408 | 0.81 | LMNA (0.56) | KDM4EALDH1A1 | |
| SCHEMBL4058468 | 0.81 | HRH3 (0.52) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4063051 | 0.81 | HRH3 (0.57) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL477889 | 0.80 | HRH3 (0.57) | ALDH1A1SIGMAR1MAPT | |
| SCHEMBL3183618 | 0.79 | HRH3 (0.60) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4649494 | 0.79 | DRD4 (0.87) | DRD4KDM4EALDH1A1HTTDRD2 | |
| SCHEMBL6031812 | 0.78 | DRD4 (1.00) | DRD4KDM4EALDH1A1HTTDRD2 | |
| SCHEMBL4058996 | 0.76 | CHKA (0.63) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL22532699 | 0.76 | DRD4 (0.79) | DRD4KDM4EALDH1A1HTTDRD2 | |
| SCHEMBL12861757 | 0.76 | DRD4 (0.79) | DRD4KDM4EALDH1A1HTTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | DRD4 2523/4885KDM4E 4287/4885ALDH1A1 275/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | DRD4 2762/4885KDM4E 3790/4885ALDH1A1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.